Advancing Alzheimer’s Disease Detection Through Blood-Based Biomarkers
On-Demand Recording
Thanks for your interest in our recent webinar in partnership with Science.
Phosphorylated tau (p-Tau), amyloid-beta (Ab) 42/40, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) are current key Alzheimer’s disease (AD) blood-based biomarkers. Interpreting results of the four biomarkers simultaneously in a clinical context is challenging due to issues such as tissue sample size, cost, and timing. A decision algorithm could aid in the interpretation, tailored to clinically relevant questions: 1) identify positive amyloid status among preclinical and prodromal AD stages, 2) discriminate AD-dementia from frontotemporal dementia (FTD), and 3) characterize AD-dementia from dementia with Lewy bodies (DLB).
This webinar discussed the development and validation of such an interpretation tool and demonstrated that the combination of p-Tau 181, GFAP, and NfL in plasma could support decision making in different clinical contexts and serve as a tool to support both detection and differential diagnosis of Alzheimer’s disease.
Viewers will:
- Learn about current and upcoming blood-based biomarkers for Alzheimer’s disease and other neuropsychiatric syndromes
- Gain insight on how multiple biomarkers are needed to sort out the complexities of AD, co-pathologies, and non-AD dementias
- Hear about the advantages and disadvantages of using these biomarkers for research and clinical correlations
- Have an opportunity to ask questions during the live broadcast
Speaker
Inge Verberk, Ph.D.
Amsterdam University Medical Centers, Amsterdam, The Netherlands
Dr. Verberk is a senior researcher at the Neurochemistry Lab of Amsterdam UMC, Amsterdam, The Netherlands. Her research focuses on the development and implementation of blood-based biomarkers for the diagnosis and prognosis of Alzheimer’s disease.